Mechanisms
A structural and clinical review of Lp(a)'s bidirectional risk and the emerging therapies targeting it (J Clin Biochem Nutr 2026)
Original title: Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers
This review by Xu and colleagues surveys lipoprotein(a) biology and management, emphasising that both extremely high and extremely low Lp(a) levels are linked to adverse outcomes, a bidirectional risk pattern that complicates simple threshold-based management. It covers Lp(a)'s distinctive structure, its genetic determinants, the metabolic pathways governing plasma concentration, and the persistent lack of standardisation across diagnostic assays. It notes that conventional lipid-lowering therapies have minimal effect on Lp(a), leaving a treatment gap that emerging Lp(a)-targeted therapeutic strategies aim to close. A concise molecular and clinical synthesis rather than a report of new data, useful chiefly for its framing of the bidirectional risk and standardisation problems.
Original abstract
Despite substantial progress in the management of cardiovascular disease (CVD), lipoprotein(a) [Lp(a)] persists as a genetically determined risk factor that remains insufficiently explored. Both extremely high and low levels of Lp(a) are linked to adverse outcomes. Current diagnostic assays for Lp(a) lack standardization, and conventional lipid-lowering therapies exert minimal effects on its levels, resulting in limited treatment options specifically targeting Lp(a). To address these gaps, we conducted a comprehensive molecular and clinical review of Lp(a), examining its unique structure, genetic determinants, metabolic pathways, and the factors influencing its plasma concentration. Furthermore, we discuss emerging therapeutic strategies aimed at targeting Lp(a).
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.